Use of surrogate antimicrobial agents to predict susceptibility to ertapenem

被引:16
作者
Friedland, IR [1 ]
Isaacs, R [1 ]
Mixson, LA [1 ]
Motyl, M [1 ]
Woods, GL [1 ]
机构
[1] Merck Res Labs, W Point, PA 19486 USA
关键词
D O I
10.1016/S0732-8893(02)00380-2
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Broth or agar dilution susceptibility test results for Enterobacteriaceae (11,775 strains), anaerobes (2888 strains), staphylococci (2206 strains), Haemophilus spp. (840 strains), group A streptococci (280 strains), group B streptococci (269 strains), Streptococcus pneumoniae (709 strains), and 160 other streptococci were analyzed to identify surrogate antimicrobial agents to predict susceptibility to ertapenem. Ertapenem MIC interpretive categories approved by the United States FDA were compared to those of imipenem, oxacillin (staphylococci), or penicillin (streptococci). Ertapenem resistance was rare (1.2%) among 8187 consecutively collected clinical isolates of Enterobacteriaceae, including a large proportion of isolates from intensive care units. Absolute categorical agreement between ertapenem and imipenem, and very major (false susceptible) and major errors (false resistant) using imipenem to predict ertapenem results were 97.2%, 0.9%, and 0.4%, respectively, for Enterobacteriaceae (10,992 strains tested against both drugs) and 99.0%, 0.2%, and 0% for anaerobes. All Haemophilus spp., groups A and B streptococci, penicillin-susceptible and -intermediate S. pneumoniae, and other penicillin-susceptible streptococci were susceptible to ertapenem. All oxacillin-susceptible Staphylococcus aureus were ertapenem susceptible, except I that was intermediate. Surrogate antimicrobial agents that can be used to reliably predict ertapenem Susceptibility by MIC tests are imipenem for Enterobacteriaceae and anaerobes, oxacillin for staphylococci, and penicillin for streptococci. (C) 2002 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:61 / 64
页数:4
相关论文
共 14 条
[1]  
Ferraro Mary Jane, 1995, P1379
[2]   In vitro activities of ertapenem (MK-0826) against clinical bacterial isolates from 11 North American medical centers [J].
Fuchs, PC ;
Barry, AL ;
Brown, SD .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (06) :1915-1918
[3]   Comparative in vitro activities of ertapenem (MK-0826) against 1,001 anaerobes isolated from human intra-abdominal infections [J].
Goldstein, EJC ;
Citron, DM ;
Merriam, CV ;
Warren, Y ;
Tyrrell, KL .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (09) :2389-2394
[4]  
GRAHAM DR, IN PRESS CLIN INFECT
[5]   In vitro antianaerobic activity of ertapenem (MK-0826) compared to seven other compounds [J].
Hoellman, DB ;
Kelly, LM ;
Credito, K ;
Anthony, L ;
Ednie, LM ;
Jacobs, MR ;
Appelbaum, PC .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (01) :220-224
[6]   In vitro activities of ertapenem (MK-0826) against recent clinical bacteria collected in Europe and Australia [J].
Livermore, DM ;
Carter, MW ;
Bagel, S ;
Wiedemann, B ;
Baquero, F ;
Loza, E ;
Endtz, HP ;
van den Braak, N ;
Fernandes, CJ ;
Fernandes, L ;
Frimodt-Moller, N ;
Rasmussen, LS ;
Giamarellou, H ;
Giamarellos-Bourboulis, E ;
Jarlier, V ;
Nguyen, J ;
Nord, CE ;
Struelens, MJ ;
Nonhoff, C ;
Turnidge, J ;
Bell, J ;
Zbinden, R ;
Pfister, S ;
Mixson, L ;
Shungu, DL .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (06) :1860-1867
[7]  
*MERCK CO INC, 2001, ERT PACK INS
[8]  
*NAT COMM CLIN LAB, 2002, M100S12 NAT COMM CLI
[9]  
National Committee for Clinical Laboratory Standards, 2000, M7A5 NAT COMM CLIN L
[10]  
National Committee for Clinical Laboratory Standards, 2001, M11A5 NAT COMM CLIN